Clinical Trial Update: Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477) [Phase 2]

View source ↗

Summary

Phase 2 study of regorafenib for urothelial cancer completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) | Phase 2 | Status: COMPLETED | Results posted: 2020-04-15